S-ClassAbout S-Class
A
APREAI Stock Diagnostic Report
Aprea Therapeutics records second consecutive surge, jumping another 22%
Aprea Therapeutics' stock price has surged for two consecutive trading days, rising by 22%.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$0.984000027179718Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support0.59
Near-Term Resistance0.85
02
FUNDAMENTALS
Financial & Fundamental Analysis
This recent surge is unrelated to performance or financial indicators, and since there has been no fundamental change in the company's financial structure, the financial impact is minimal.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price has surpassed the resistance level of 0.85, but further upside potential is limited. In the future, the level of 0.59 may serve as a support line.
Support0.59
Resistance0.85
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The consecutive surges of 22% and 26% reflect the market's short-term buying sentiment; however, this is merely a reaction to the price itself, rather than the growth targets or new contracts directly presented by the company. The high RSI and trading volume reaching 58 times indicate short-term buying pressure, but also imply a risk of overbought conditions.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-25)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.